CBL and hepatocellular carcinoma: Taken together, these results indicate that PSMD9 inhibits c-Cbl expression and subsequently decreases EGFR ubiquitination and endocytosis from the cell membrane and suppresses ERK1/2 and Akt activation, which contributes to HCC progression.